Cargando…
CRISPR base editing applications for identifying cancer-driving mutations
CRISPR base editing technology is a promising genome editing tool as (i) it does not require a DNA template to introduce mutations and (ii) it avoids creating DNA double-strand breaks, which can lead to unintended chromosomal alterations or elicit an unwanted DNA damage response. Given many cancers...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925010/ https://www.ncbi.nlm.nih.gov/pubmed/33449100 http://dx.doi.org/10.1042/BST20200550 |
_version_ | 1783659203186917376 |
---|---|
author | Pal, Martin Herold, Marco J. |
author_facet | Pal, Martin Herold, Marco J. |
author_sort | Pal, Martin |
collection | PubMed |
description | CRISPR base editing technology is a promising genome editing tool as (i) it does not require a DNA template to introduce mutations and (ii) it avoids creating DNA double-strand breaks, which can lead to unintended chromosomal alterations or elicit an unwanted DNA damage response. Given many cancers originate from point mutations in cancer-driving genes, the application of base editing for either modelling tumour development, therapeutic editing, or functional screening is of great promise. In this review, we summarise current DNA base editing technologies and will discuss recent advancements and existing hurdles for its usage in cancer research. |
format | Online Article Text |
id | pubmed-7925010 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Portland Press Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79250102021-03-08 CRISPR base editing applications for identifying cancer-driving mutations Pal, Martin Herold, Marco J. Biochem Soc Trans Review Articles CRISPR base editing technology is a promising genome editing tool as (i) it does not require a DNA template to introduce mutations and (ii) it avoids creating DNA double-strand breaks, which can lead to unintended chromosomal alterations or elicit an unwanted DNA damage response. Given many cancers originate from point mutations in cancer-driving genes, the application of base editing for either modelling tumour development, therapeutic editing, or functional screening is of great promise. In this review, we summarise current DNA base editing technologies and will discuss recent advancements and existing hurdles for its usage in cancer research. Portland Press Ltd. 2021-02-26 2021-01-15 /pmc/articles/PMC7925010/ /pubmed/33449100 http://dx.doi.org/10.1042/BST20200550 Text en © 2021 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) . Open access for this article was enabled by the participation of Walter and Eliza Hall Institute in an all-inclusive Read & Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with CAUL. |
spellingShingle | Review Articles Pal, Martin Herold, Marco J. CRISPR base editing applications for identifying cancer-driving mutations |
title | CRISPR base editing applications for identifying cancer-driving mutations |
title_full | CRISPR base editing applications for identifying cancer-driving mutations |
title_fullStr | CRISPR base editing applications for identifying cancer-driving mutations |
title_full_unstemmed | CRISPR base editing applications for identifying cancer-driving mutations |
title_short | CRISPR base editing applications for identifying cancer-driving mutations |
title_sort | crispr base editing applications for identifying cancer-driving mutations |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7925010/ https://www.ncbi.nlm.nih.gov/pubmed/33449100 http://dx.doi.org/10.1042/BST20200550 |
work_keys_str_mv | AT palmartin crisprbaseeditingapplicationsforidentifyingcancerdrivingmutations AT heroldmarcoj crisprbaseeditingapplicationsforidentifyingcancerdrivingmutations |